No information is available on the clinical use of cabozantinib during breastfeeding. Because cabozantinib is more than 97% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life ranges from 55 to 99 hours and it might accumulate in the infant. The manufacturer recommends that breastfeeding be discontinued during cabozantinib therapy and for 4 months after the last dose.
关于卡博替尼在母乳喂养期间的临床应用尚无可用信息。由于卡博替尼与血浆蛋白的结合率超过97%，其在乳汁中的含量可能较低。然而，其半衰期为55至99小时，可能会在婴儿体内蓄积。制造商建议在卡博替尼治疗期间及最后一剂后4个月内停止母乳喂养。
